A Phase 1 interventional study of HN2301 injection in Generalized Myasthenia Gravis, sponsored by Shenzhen MagicRNA Biotechnology Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Shenzhen MagicRNA Biotechnology Co., Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Myasthenia Gravis with a site in China — 48 open to participants now, 60 under way, 17 of them phase 3. Myasthenia Gravis · China.
Among the 88 studies in Myasthenia Gravis with a site in China, this one is the 61st largest by planned enrollment of the 67 interventional ones that give a count, is one of 18 that started in 2026, is one of 25 in phase 1, reaches primary completion later than 30 of the 59 other live ones, and was the 81st registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →48 of the 88 studies in Myasthenia Gravis with a site in China are open now. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in China, United States, France and 4 more countries
Ages 18+
Guangdong Hengrui Pharmaceutical Co., Ltd · Sites in China
Ages 18–75
Alexion Pharmaceuticals, Inc. · Sites in China
Ages 18–130
UCB Biopharma SRL · Sites in China, United States, Canada and 6 more countries
Ages 18+
Tongji Hospital · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 8 · Phase 3 26 · Phase 4 1
First in 2011; this study’s year is marked. 18 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6 is below the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 40 across the 67 interventional studies, 297 across the 21 observational. Of the 17 that completed or were terminated, 2 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 88 have an industry lead sponsor. The 10 most frequent:
Shenzhen MagicRNA Biotechnology Co., Ltd is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Shenzhen MagicRNA Biotechnology Co., Ltd has 2 studies filed under Myasthenia Gravis — fewer than ten, so there is no comparison to draw.
23 of the studies in Myasthenia Gravis with a site in China that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06447597Phase 3Shanghai Jiaolian Drug Research and Development Co., LtdA Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis. | 2026-12-30 |
| NCT07249632Phase 3RemeGen Co., Ltd.A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) | 2026-12-31 |
| NCT06456580Phase 3Vor BiopharmaA Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | 2027-03 |
| NCT06517758Phase 3Novartis PharmaceuticalsA Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | 2027-04-30 |
| NCT07231523Phase 3Shanghai Zhongshan HospitalEFG vs IVIG in TAMG | 2027-06-01 |
Add all 23 to your calendar (.ics) → With an account.
Among the 88 studies in Myasthenia Gravis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open label, single arm study, to evaluate safety, tolerability and preliminary efficacy of HN2301 in patients with Generalized Myasthenia Gravis.
This study consists of a screening period of up to 4 weeks, a treatment period, and a follow-up period of 1 year.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive HN2301 Injection at the specified dose level and on the specified study days.
Drug: HN2301 injection
Dosing will begin at a lower dose level and may be escalated to dose levels considered safe and potentially effective according to the study protocol.
Also known as: in vivo CAR-T
Incidence of treatment-emergent adverse events (TEAEs)
Incidence, nature, and severity of treatment-emergent adverse events, assessed according to the study protocol and applicable toxicity grading criteria.
Time frame: Up to 3 months
in vivo CAR T cell production
Assessment of in vivo CAR-T cell production, defined by the proportion of CAR-expressing T cells in peripheral blood as measured by flow cytometry.
Time frame: Up to14 days
Absolute B-cell count in peripheral blood
Assessment of peripheral blood absolute B-cell count (cells/μL), including naive B cells and memory B cells, by flow cytometry.
Time frame: Up to 12 months
Changes from baseline in Myasthenia Gravis Activities of Daily Living(MG-ADL) score
Proportion of patients ≥2 points. A total score can fall between 0 and 24, with a higher score representing a more significant degree of disease activity.
Time frame: Up to 12 months]
Changes from baseline in Myasthenia Gravis Composite (MGC) score
Proportion of patients ≥3-point reduction.The total score is 50 points. The higher the score, the more severe the condition is indicated.
Time frame: Up to 12 months
Changes from baseline in Quantitative Myasthenia Gravis (QMG) score
Proportion of patients ≥3-point reduction. To assess the muscle strength and endurance of the affected muscles in patients with myasthenia gravis, thereby reflecting the severity of the disease,including 8 items, each scored on a scale of 0 to 3, with 3 indicating the most severe degree.
Time frame: Up to 12 months]
Changes from baseline in revised Myasthenia Gravis Quality of Life-15 score (MG-QOL15r)
To assess important aspects of the patient's experience related to MG, scores each of 15 items 0-2 (max score 30).The higher the score, the worse the patient's quality of life.
Time frame: Up to 12 months
Changes in acetylcholine receptor (AchR) antibody levels after treatment
Differences in AchR antibody post-administration vs. baseline
Time frame: Up to 12 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for May 2027, 5 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HN2301
Shenzhen MagicRNA Biotechnology Co., Ltd